Wedoany.com Report-Nov. 28, Valneva has announced the closure of its 3,178 m² facility in Nantes, France, consolidating French operations at its original base in Lyon.

The French vaccine specialist plans to close its 3,178m² facility in Nantes, France.

The decision will result in the termination of 30 positions from a company-wide workforce of 713 at the end of 2024. A Valneva spokesperson confirmed that no research programmes will be discontinued; all R&D activities previously conducted in Nantes will transfer to the company’s primary research centre in Vienna.

The restructuring follows a recent downward revision of 2025 product sales guidance to €155–170 million, reduced from the earlier €170–180 million range. The adjustment was driven mainly by the US FDA’s suspension of Valneva’s chikungunya vaccine Ixchiq over safety concerns, preventing further shipments and sales in the US market – the product’s largest commercial segment. Valneva has submitted a response to the FDA and awaits further guidance.

Ixchiq remains one of Valneva’s three marketed vaccines, alongside Ixiaro/Jespect (Japanese encephalitis) and Dukoral (cholera).

On the same day the Nantes closure was disclosed, Valneva and partner Pfizer released complete Phase II data for their jointly developed Lyme disease vaccine candidate VLA15. The results showed strong immune responses and a favourable safety profile in all age groups six months after the third booster dose. Subject to successful Phase III outcomes, Pfizer intends to file regulatory submissions with the FDA and European Medicines Agency in 2026.

The Nantes site consolidation forms part of Valneva’s ongoing efforts to streamline operations and focus resources on core commercial and pipeline programmes.